Adagene Inc. (ADAG) NASDAQ
3.74
-0.04(-1.06%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Adagene Inc.
Sector
Healthcare
Industry
Biotechnology
Employees
138
First IPO Date
February 09, 2021
Key Executives
| Name | Title | Pay | Year Born |
| Peter Luo | Co- Founder, Chairman, Chief Executive Officer and President of R&D | 0 | 1966 |
| Guizhong Liu | Senior Vice President of Early Drug Discovery | 0 | 1971 |
| Jiping Zha | Executive Vice President of Clinical Development | 0 | N/A |
| Qinghai Zhao | Chief Manufacturing Officer | 0 | 1961 |
| Songmao Zheng | Senior Vice President of Clinical Pharmacology & Quantitative Sciences | 0 | N/A |
| Alexander Goergen | VP & Head of Business Development | 0 | 1987 |
| Man Kin Tam | Chief Financial Officer & Director | 0 | 1977 |
| Ling Zhou | Executive Director & Head of Human Resources | 0 | N/A |
| Xiaohong She | Senior VP & Head of Clinical Operations | 0 | 1967 |
| Yan Li | Senior Vice President of Bioinformatics & Information Technology | 0 | 1975 |
Description
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.
